Video

Our team behind the scenes at SXSW | Patient Stratification in Target ID, OMICS data

BenevolentAI develops AI models to help scientists better define underlying mechanisms of disease in very specific patients groups.

Looking at patient clinical and biomedical data we try to dig into molecular-level detail to redefine the disease and better endotyping for two main purposes: target identification and designing better clinical trials.

There is an abundance of patient data created e.g. electronic health records or genome sequencing. With increasing amounts of data being generated, we need AI models to help make meaningful discoveries.

Precision medicine is the future of medicine. Our belief is that by better understanding the underlying mechanisms of diseases in patients and identifying more specific and precise endotypes, we will be able to provide better medicines that are efficient in the specific patients groups they are developed for.

Watch Poojitha Ojamies, a Solutions Architect at BenevolentAI discuss how our team uses AI and machine learning to improve patient endotyping in multi-omics for target identification.  

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022